Season 03: episode 03
This week’s episode features a fascinating conversation with Dr Samin Saeed, UK Chief Scientific Officer and Medical Director at Novartis UK.
Samin discusses a whole host of medical affairs-related issues, including the transition from medicine to pharma, cross-functionality, commercial versus medical affairs, and lots more besides, including a fascinating discussion about leadership, company culture and soft skills development.
And, in ‘news you might have missed’, there’s an update from the Healthcare Businesswomen’s Association on the gender pay gap in European life sciences – good news to an extent – and details of new investment from Novartis in bolstering its development and manufacturing of next generation biotherapeutics.
A little more on GOLD’s guest…
Dr Samin Saeed is the UK Chief Scientific Officer and Medical Director at Novartis UK. She studied medicine at King’s College London and practised medicine for around five years, undertaking basic surgical training, before studying for a diploma in pharmaceutical medicine and transitioning to pharma and the world of medical affairs. She started out in the industry as a Medical Affairs Manager and worked her way up the ranks, working at several pharma companies over the last 15 years such as Merck, GSK and now Novartis, as well as in medical affairs consultancy.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Click here to subscribe to the weekly newsletter for more insights from GOLD.